GMAB News and Press, Genmab A/S From 02/20/24

2024-02-20 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-14 16:17:11 ET Genmab A/S (GMAB) Q4 2023 Results Conference Call February 14, 2024 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President and Chief Executive Officer Anthony Mancini - Executive Vice President & COO Anthony Pagano -...

2024-02-14 12:59:28 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Genmab reports FY results Genmab FY 2023 Earnings Preview Seeking Alpha’s Quant ...

2024-02-14 11:29:41 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Genmab FY 2023 Earnings Preview Pfizer-Genmab cervical cancer drug gets accepted for EU review ...

Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for...

Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...

2024-02-13 11:11:35 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Pfizer-Genmab cervical cancer drug gets accepted for EU review Johnson & Johnson wins arbit...

2024-02-02 07:13:49 ET More on Genmab, Pfizer, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript U.S. govt. opens bids in Medica...

Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab ve...

2024-01-30 16:40:26 ET More on Johnson & Johnson Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy' Johnson & Johnson 2023 Q4 - Results -...